News & Press

First Patient Dosed in Phase II Study


Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II

learn more

FDA Clearance of IND


Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain

learn more

Abstract Accepted to OARSI 2020


Moebius Announces Acceptance of Abstract to OARSI 2020 Congress Showing MM-II’s Ability to Coat Cartilage in-vivo and Reduce Friction and Wear in ex-vivo Cartilage Models.

learn more


Sun Pharma & Moebius Medical


Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis

learn more

Tech Tour Healthcare Summit


Moebius selected to present at Tech Tour Healthcare Summit

learn more

MIXiii BioMed 2017

Moebius shares its experience of negotiating with TTOs at MIXiii BioMed 2017 Conference

Startup Nation Conference, Miami

Moebius invited to participate in Startup Nation Conference – Miami

Moebius presents poster at OARSI

Moebius presents poster at OARSI highlighting results of first prospective randomized double-blinded study

learn more

American College of Rheumatology Meeting

Highlights of Moebius’s RCT presented at American College of Rheumatology Meeting

learn more

Poster presentation at AAOS

Poster presentation at AAOS demonstrating Safety and Efficacy of Liposome Intraarticular Injection in Moderate Knee Osteoarthritis